Groups
Main Sector
Investor Type
Service Provider Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Index
Countries
Reset

Chris Davey Ireland

Marvao Medical is an early stage medical device company founded in 2006 to develop and commercialize products that reduce the incidence of catheter related bloodstream infections. Our first 2 product lines target a $1B global market opportunity. The first product line is now FDA cleared and is being evaluated at 3 centers in the US with very positive results. We are seeking to raise funds in mid/late 2015 to support full commercialization of this product which will enable the company to become highly profitable in early 2017.

 

Website:
www.marvaomedical.com
Year Founded
2006
Medtech Subsector
Indication
Medtech Phase of Development
Technology Overview
We have developed a technology platform that aims to reduce the risk of catheter related bloodstream infections (CRBSI) in patients who require long term vascular access. We have received FDA clearance for our first commercial application of this platform, a hemodialysis (HD) catheter, which is now being clinically evaluated at 3 centres in the US. Our next commercial application is a line of central venous catheters used to deliver chemotherapy, antibiotics, nutrition, and hydration. The overall global opportunity for these two applications is >$1B.
Alliance & Collaborations
In 2008 we entered into a strategic OEM partnership with Harmac Medical Products. Harmac has major manufacturing facilities in the US, Ireland, and Mexico. They have supported our product development programs (including our FDA applications), built our clinical evaluation product, and are now well positioned to rapidly scale up production in 2015.
Supporting Metrics or Evidence
Clinically reported CRBSI rates for HD catheters range between 1.6 and 5.5 events/1000 catheter days. Our HD catheter clinical evaluation has accumulated 3000 catheter days to date with only 1 reported CRBSI event, yielding a rate of 0.3/1000 catheter days. These results have attracted significant interest from healthcare providers who recognise our product's potential to help deliver significantly better care at lower cost within their centers.
Current Financing Needs
Marvao is fully funded to meet our product development and clinical evaluation milestones in 2015. We are looking for new investors to come in alongside our existing investors in Q3 2015 to support our 2016 commercialization program. Our financial model indicates that a quantum of $2.0 - $2.5M is needed to enable the company to become profitable in early 2017.
Current Timeline
In January 2015 we will start the 2nd phase of our clinical evaluation by working directly with one of the world’s two largest HD service providers. The objective is to measure CRBSI rates over 10,000 catheter days across multiple centres in their network. This company is also the market’s single largest purchaser of HD catheters. We expect that low CRBSI rates observed over the course of this evaluation will translate into a significant catheter supply agreement in 2016.
IP Status
Our core technology is currently protected by 4 issued US patents, with 4 additional applications underway. We are in the process of further expanding this portfolio to cover commercially critical product features beyond our core technology.
Recent Milestones
Passed our 2nd FDA QSIT audit in Q3 2014. Passed our annual ISO 13485 certification audit in Q3 2014. Third HD catheter 510k clearance obtained from the FDA in Q4 2014
Management Team Highlights
Eamonn Hobbs: Chairman of the Board. Mark Saab: Co Founder, Principal Investor, Non Executive Director. Chris Davey: Co Founder, CEO
Marvao Medical Devices
CEO 

Daniel O'Mahony Ireland

Seroba Kernel is a venture capital firm based in Dublin, Ireland, with representatives in the United Kingdom. The firm has approximately €100M AUM and focuses solely on the life sciences. The firm has 2 funds and plans to raise a third fund in the near future. The firm typically allocates between €5-7M of equity over the life of the investment. The firm primarily invests in companies that are based in Ireland and Europe. Exceptional opportunities in North America will also be considered. The firm is actively seeking new investment opportunities.

Website:
http://www.seroba-kernel.com
Year Founded
2001
Investor Type
Sector Interest
Biotech Subsector
Medtech Subsector
Indication
Biotech Phase of Development
Medtech Phase of Development
Capital Structure Preference
Investment Stage Preference
Seroba Kernel Life Sciences
Partner